Published in Prim Care Companion CNS Disord on January 01, 2011
Sleep disturbance, depression and pain in adults with sickle cell disease. BMC Psychiatry (2014) 0.94
Depression and quality of life in children with sickle cell disease: the effect of social support. BMC Psychiatry (2015) 0.80
Psychiatric problems in children and adolescents with sickle cell disease, based on parent and teacher reports. Turk J Haematol (2012) 0.79
Transition Needs of Adolescents With Sickle Cell Disease. Am J Occup Ther (2015) 0.75
Opioid pseudoaddiction--an iatrogenic syndrome. Pain (1989) 2.41
Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiol Drug Saf (2010) 1.78
Medical care utilization and mortality in sickle cell disease: a population-based study. Am J Hematol (2005) 1.61
A comparison of multivariable regression models to analyse cost data. J Eval Clin Pract (2006) 1.29
Depression and anxiety in adults with sickle cell disease: the PiSCES project. Psychosom Med (2007) 1.29
Identification and validation of lupus nephritis cases using administrative data. Lupus (2010) 1.28
Psychological and social concomitants of sickle cell anemia in adolescents. J Pediatr Psychol (1986) 1.27
Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy (2007) 1.24
Quality of life among adolescents with sickle cell disease: mediation of pain by internalizing symptoms and parenting stress. Health Qual Life Outcomes (2008) 1.22
Depression in sickle cell disease. J Natl Med Assoc (2003) 1.18
Administrative data sets and health services research on hemoglobinopathies: a review of the literature. Am J Prev Med (2010) 1.11
Daily functioning and quality of life in children with sickle cell disease pain: relationship with family and neighborhood socioeconomic distress. J Pain (2008) 1.09
Physicians' attitude and practices in sickle cell disease pain management. J Palliat Care (2005) 1.09
Psychological complications in sickle cell disease. Br J Haematol (2005) 1.07
Psychiatry in chronic pain: a review and update. Curr Psychiatry Rep (2005) 1.03
Management of neuropathic pain: translating mechanistic advances and evidence-based research into clinical practice. Clin J Pain (2006) 0.95
Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. Am J Hematol (2010) 0.95
Association between elevated depressive symptoms and clinical disease severity in African-American adults with sickle cell disease. J Natl Med Assoc (2006) 0.94
Antidepressant and anticonvulsant medication for chronic pain. Phys Med Rehabil Clin N Am (2006) 0.94
Physical growth, sexual maturation, body image and sickle cell disease. J Natl Med Assoc (2000) 0.94
Anxiety and depression in children and adolescents with sickle cell disease. Curr Psychiatry Rep (2007) 0.91
Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study. J Clin Psychiatry (2009) 0.90
Negative thinking as a coping strategy mediator of pain and internalizing symptoms in adolescents with sickle cell disease. J Behav Med (2007) 0.90
Who is paying the bills? Health care costs for musculoskeletal back disorders, Washington State Union Carpenters, 1989-2003. J Occup Environ Med (2009) 0.90
Factors that influence adolescent adaptation to sickle cell disease. J Pediatr Psychol (2000) 0.89
Painful peripheral neuropathy and its nonsurgical treatment. Muscle Nerve (2004) 0.88
Antidepressant pharmacotherapy: considerations for the pain clinician. Pain Pract (2003) 0.88
Symptoms of depression and anxiety in adolescents with sickle cell disease: the role of intrapersonal characteristics and stress processing variables. Child Psychiatry Hum Dev (2009) 0.88
Pain management in children and adolescents with sickle cell disease. Am J Hematol (2010) 0.85
Non-pharmacologic management of sickle cell pain. Hematology (2004) 0.85
Neuropathic agents and pain. New strategies. Biomed Pharmacother (2006) 0.85
Sickle cell disease: a stigmatizing condition that may lead to depression. Issues Ment Health Nurs (2005) 0.84
Hematologic problems in psychosomatic medicine. Psychiatr Clin North Am (2007) 0.82
Physical and mental health in adults hospitalized with sickle cell disease: impact on resource use. J Natl Med Assoc (2009) 0.81
Adjustment and coping in adolescents with sickle cell disease. Ann N Y Acad Sci (1989) 0.80
The assessment and management of chronic pain in children. Paediatr Drugs (2002) 0.80
Depression, suicidal ideation, and attempts in black patients with sickle cell disease. J Natl Med Assoc (2009) 0.78
Adverse events associated with psychotropic treatment in African American children and adolescents. J Natl Med Assoc (2010) 0.77
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord (2009) 3.56
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord (2012) 3.01
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry (2008) 2.86
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord (2009) 2.17
Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry (2007) 2.15
Novel investigational drugs targeting IL-6 signaling for the treatment of depression. Expert Opin Investig Drugs (2015) 2.07
A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder. J Clin Psychiatry (2010) 1.79
Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry (2009) 1.70
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry (2012) 1.64
Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord (2008) 1.49
Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009. South Med J (2011) 1.48
Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications. Clin Schizophr Relat Psychoses (2010) 1.44
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord (2006) 1.43
Is the cerebellum relevant in the circuitry of neuropsychiatric disorders? J Psychiatry Neurosci (2005) 1.35
Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry (2007) 1.34
The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry (2012) 1.18
Predictors of self-reported antidepressant adherence. Behav Med (2007) 1.16
Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. J Psychiatry Neurosci (2009) 1.16
Letter to editor: Incident depression increases medical utilization in Medicaid patients with hypertension. Expert Rev Cardiovasc Ther (2014) 1.07
The impact of obesity on quality of life. Best Pract Res Clin Endocrinol Metab (2013) 1.04
Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother (2012) 0.98
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry (2002) 0.95
The neurobiology of the EEG biomarker as a predictor of treatment response in depression. Neuropharmacology (2012) 0.95
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. Ann Clin Psychiatry (2012) 0.95
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry (2012) 0.95
Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Med (2010) 0.95
Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet (2006) 0.95
Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. Am J Hematol (2010) 0.95
The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles. Ann Clin Psychiatry (2012) 0.94
Major Depressive Disorder and Bipolar Disorder Predispose Youth to Accelerated Atherosclerosis and Early Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation (2015) 0.93
Differentiating bipolar disorders from major depressive disorders: treatment implications. Ann Clin Psychiatry (2007) 0.92
The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology (2009) 0.91
Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res (2012) 0.89
What Are the Implications of the STAR*D Trial for Primary Care? A Review and Synthesis. Prim Care Companion J Clin Psychiatry (2008) 0.89
Aerobic physical exercise as a possible treatment for neurocognitive dysfunction in bipolar disorder. Postgrad Med (2010) 0.88
The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom (2014) 0.87
Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother (2011) 0.87
Long-acting risperidone: a review of its role in the treatment of bipolar disorder. Adv Ther (2009) 0.86
Frequency and correlates of gambling problems in outpatients with major depressive disorder and bipolar disorder. Can J Psychiatry (2010) 0.86
Exercise and bipolar disorder: a review of neurobiological mediators. Neuromolecular Med (2009) 0.86
Relationship between regional brain metabolism, illness severity and age in depressed subjects. Psychiatry Res (2007) 0.86
Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration. J Psychiatr Res (2013) 0.86
Crosstalk between metabolic and neuropsychiatric disorders. F1000 Biol Rep (2012) 0.86
The effect of bariatric surgery on psychiatric course among patients with bipolar disorder. Bipolar Disord (2013) 0.86
Neurocognitive-genetic and neuroimaging-genetic research paradigms in schizophrenia and bipolar disorder. J Neural Transm (Vienna) (2011) 0.86
Beyond pharmacotherapy: understanding the links between obesity and chronic mental illness. Can J Psychiatry (2012) 0.85
Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol (2008) 0.85
Assessing the prevalence of depression among individuals with diabetes in a Medicaid managed-care program. Int J Psychiatry Med (2008) 0.85
Pain management in children and adolescents with sickle cell disease. Am J Hematol (2010) 0.85
Towards a multifactorial approach for prediction of bipolar disorder in at risk populations. J Affect Disord (2012) 0.85
An approach to managing depression. Defining and measuring outcomes. Can Fam Physician (2004) 0.84
Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf (2015) 0.84
Relation between cigarette smoking and cognitive function in euthymic individuals with bipolar disorder. Pharmacol Biochem Behav (2008) 0.84
Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation. J Affect Disord (2013) 0.83
Bipolar depression: trial-based insights to guide patient care. Dialogues Clin Neurosci (2008) 0.83
Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. Neurosci Biobehav Rev (2013) 0.83
Correlates of metabolic abnormalities in bipolar I disorder at initiation of acute phase treatment. Psychiatry Investig (2009) 0.83
Neuroimaging approaches in mood disorders: technique and clinical implications. Ann Clin Psychiatry (2007) 0.83
Obesity and bipolar disorder: synergistic neurotoxic effects? Adv Ther (2013) 0.82
Inflammatory cytokines as an underlying mechanism of the comorbidity between bipolar disorder and migraine. Med Hypotheses (2012) 0.82
A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect. J Clin Psychopharmacol (2016) 0.82
Body fat distribution and associations with metabolic and clinical characteristics in bipolar individuals. Eur Arch Psychiatry Clin Neurosci (2014) 0.82
Prevalence, treatment, and outcomes of renal conditions in pediatric sickle cell disease. South Med J (2011) 0.81
Atypical antipsychotic tolerability and switching strategies in bipolar disorder. Expert Opin Pharmacother (2010) 0.81
Teratogenesis associated with antibipolar agents. Adv Ther (2009) 0.81
Screening for bipolar disorder in the primary care: a Brazilian survey. J Affect Disord (2012) 0.81
Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. Can J Psychiatry (2012) 0.80
Psychotropic drugs and renal failure: translating the evidence for clinical practice. Adv Ther (2009) 0.80
Endometrial cancer and antidepressants: A nationwide population-based study. Medicine (Baltimore) (2016) 0.80
The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. Bipolar Disord (2013) 0.79
Comorbidity in bipolar disorder: clinical and research opportunities. Bipolar Disord (2006) 0.79
Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. Bipolar Disord (2013) 0.79
A theoretical framework informing research about the role of stress in the pathophysiology of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.79
Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders? Expert Opin Investig Drugs (2008) 0.79
Admixture analysis of age at onset in major depressive disorder. Gen Hosp Psychiatry (2012) 0.79
Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. J Clin Psychopharmacol (2013) 0.79
Correlates of incident bipolar disorder in children and adolescents diagnosed with attention-deficit/hyperactivity disorder. J Clin Psychiatry (2014) 0.78
The risk of developing type 2 diabetes mellitus associated with psychotropic drug use in children and adolescents: a retrospective cohort analysis. Prim Care Companion CNS Disord (2012) 0.78
Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: relevance as an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.78
Risk factors for incident major depressive disorder in children and adolescents with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry (2014) 0.78
Effects of alpha-lipoic acid in an animal model of mania induced by D-amphetamine. Bipolar Disord (2012) 0.78
Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: a pooled, post hoc analysis from the asenapine development program. J Affect Disord (2013) 0.78
Childhood treatment with psychotropic medication and development of comorbid medical conditions in adolescent-onset bipolar disorder. Hum Psychopharmacol (2011) 0.78
Individual risk factors and complexity associated with congenital heart disease in a pediatric medicaid cohort. South Med J (2013) 0.78
Prevalence of treatment, risk factors, and management of atrial septal defects in a pediatric Medicaid cohort. Pediatr Cardiol (2013) 0.78
Early switching strategies in antidepressant non-responders: current evidence and future research directions. CNS Drugs (2014) 0.78
Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways. J Psychopharmacol (2013) 0.78
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders. Ann Clin Psychiatry (2012) 0.78
Demographic characteristics and behavioral risk factors of HIV infection and association with survival among individuals 50 years or older. South Med J (2011) 0.77
Improving outcomes in patients with bipolar depression: a comprehensive review. J Clin Psychiatry (2015) 0.77
Cardiovascular and neurological adverse events associated with antidepressant treatment in children and adolescents. J Child Neurol (2009) 0.77
Discontinued psychiatric drugs in 2008. Expert Opin Investig Drugs (2009) 0.77
Economic grand rounds: economic costs of failure to monitor adverse effects of second-generation antipsychotics: an underestimated factor. Psychiatr Serv (2012) 0.77
Clinical translation of neuroimaging research in mood disorders. Psychiatry (Edgmont) (2006) 0.77
Desvenlafaxine for the treatment of major depressive disorder. Expert Opin Pharmacother (2014) 0.77
Fasting Blood Glucose and Depressive Mood among Patients with Mental Illness in a Medicaid Managed Care Program. Depress Res Treat (2011) 0.77